Literature DB >> 11936998

Primitive neuroectodermal tumors/medulloblastoma.

Michael D Weil1.   

Abstract

The therapy for medulloblastoma/primitive neuroectodermal tumors of the central nervous system is surgery, followed by combination chemo-radiotherapy. The radiation field is the entire craniospinal axis, which is only avoided when treating infants. The treatment is, therefore, lengthy and toxic. Less aggressive therapy is given to patients who clinically appear to have less evidence of disease. Intensive basic research has begun to identify genetic factors of the disease, but these remain far from clinical application.

Entities:  

Mesh:

Year:  2002        PMID: 11936998     DOI: 10.1007/s11910-002-0078-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  45 in total

1.  Levels of cadmium, lead, and mercury in human brain tumors.

Authors:  I Al-Saleh; N Shinwari
Journal:  Biol Trace Elem Res       Date:  2001-03       Impact factor: 3.738

2.  Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma.

Authors:  E C Halperin; D M Watson; S L George
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

3.  Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis.

Authors:  S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Influence of a child's sex on medulloblastoma outcome.

Authors:  M D Weil; K Lamborn; M S Edwards; W M Wara
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

5.  Differentiation, proliferation and apoptosis in primary and recurrent primitive neuroectodermal tumors of childhood.

Authors:  D P Székessy; G Stoltenburg-Didinger
Journal:  Childs Nerv Syst       Date:  2001-05       Impact factor: 1.475

6.  Mutism after surgical removal of a cerebellar tumor: two case reports.

Authors:  A Di Cataldo; C Dollo; M Astuto; M La Spina; S Ippolito; M Papotto; S Giuffrida
Journal:  Pediatr Hematol Oncol       Date:  2001-03       Impact factor: 1.969

7.  Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.

Authors:  M C Frühwald; M S O'Dorisio; Z Dai; S M Tanner; D A Balster; X Gao; F A Wright; C Plass
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

8.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.

Authors:  M D Ris; R Packer; J Goldwein; D Jones-Wallace; J M Boyett
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

9.  Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas.

Authors:  R P Dahmen; A Koch; D Denkhaus; J C Tonn; N Sörensen; F Berthold; J Behrens; W Birchmeier; O D Wiestler; T Pietsch
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

10.  Clinical and molecular stratification of disease risk in medulloblastoma.

Authors:  R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

View more
  1 in total

1.  Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts.

Authors:  Pascal Vachon; Christiane Girard; Yves Théorêt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.